1 No reports describing the use of pancreatic EUS TCB in pediatric patients have been found. The aim of our report was to determine the

diagnostic utility and safety of pancreatic EUS TCB in pediatric patients for evaluating possible AIP. In this retrospective study, we reviewed a prospectively maintained EUS database to identify all pediatric patients who underwent EUS TCB at Mayo Clinic, Rochester, for suspicion of AIP. The Institutional Review Board granted study approval, and informed consent was obtained from the patient, parent, or guardian for all procedures. General anesthesia was administered in each patient. A curvilinear echoendoscope (UC140P-AL5; Olympus America, Center Valley, PA, USA) was inserted and TCB specimens (Quick-Core; Wilson-Cook, Winston-Salem, NC, USA) Pexidartinib datasheet were obtained in standard fashion and placed in formalin before submitting BMS-354825 mouse the specimen to pathology.2, 3 and 4 Given the retrospective nature of this report, there was no standardized algorithm for obtaining pancreatic biopsy specimens. However, in keeping with our approach in adults, for a high clinical suspicion of AIP based on either the patient’s clinical presentation or EUS characteristics, TCB specimens were obtained without FNA. We did not the use FNA in this setting given the poor diagnostic sensitivity of FNA, in particular for type 2 AIP. EUS TCB was performed

rather than EUS-guided ProCore given the safety and high diagnostic sensitivity of TCB in our institution and diminutive specimens obtained with the ProCore needle relative to the TCB device. One patient underwent FNA (patient 9) due to concern regarding anticipated difficulty performing TCB. However, the in-room cytopathology

review demonstrated a hypocellular specimen and no evidence of a tissue core sample was found, thereby prompting TCB. Medical records were retrospectively reviewed to obtain clinical, imaging, EUS, and pathology data. A dedicated GI pathologist, who was blinded to the clinical data and EUS FNA interpretation reported in the medical record, Chlormezanone re-examined the histologic samples. The final diagnosis was determined by a combination of clinical, outcome, laboratory, and imaging data.5 For AIP, the diagnostic criteria were based on established norms.5, 6, 7 and 8 The pathologists reread the specimens to ensure the accuracy of the initial findings/interpretation and to avoid over-diagnosis as may occur with the use of insufficiently stringent criteria. The official and reread specimens correlated in each patient. All complications were prospectively tracked and logged in the database. Descriptive statistics was used to analyze the data. Nine patients (4 boys, mean age 13.6 years, range, 9-18 years) were identified who underwent pancreatic EUS TCB between May 2007 and July 2012.